anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention provides a novel method for the therapeutic treatment of diverse grade injuries caused by human papilloma virus (HPV) in the cervix through the administration of etoposide in vaginal ovules by means of a plastic device useful for self-applying the medicine in the genital tract of the user. The invention comprises three developments: 1. The development of a solution useful for maintaining in a stable and accurate manner the required concentration of the etoposide, which is compatible with the tissues of the genital tract so as to act against the injuries caused by the human papilloma virus (HPV). 2. The development of a soft gelatine ovule containing the etoposide in a required therapeutic dose and concentration in a stable manner, said ovules presenting a suitable size for being compatible with the genital tract and which due to the effect of the fluid of said zone and the heat of the body can be dissolved, thereby releasing the etoposide in the correct place. 3. The design of a plastic device that is useful for introducing the soft gelatine ovule into the genital tract of the patient so as to position the same in the cervix. The application of the aforementioned developments allows an easy, safe and no side effects treatment to be obtained, which provides the patient with the possibility of carrying out said process in an independent and ambulatory manner, thereby reducing indirect costs and fillings of discomfort associated with gynaecological examinations.
The present invention relates to methods of treatment of programmed cell death (apoptosis) through the use of the HSV-1 gene γ 1 34.5 or the product of its expression, ICP34.5. The gene and its expression have been demonstrated to be.required for HSV-1 neurovirulence, and in particular, to act as an inhibitor of neuronal programmed cell death which allows for viral replication. Use of the gene therapy, or the protein itself, can be expected to result in inhibition of programmed cell death in various neurodegenerative diseases. This invention also relates to novel vectors for gene therapy, including modified herpes virus. Methods are presented for conducting assays for substances capable of mimicing, potentiating or inhibiting the expression of γ 1 34.5 or the activity of ICP34.5. Also, methods are disclosed for the treatment of tumorogenic diseases, including cancer, and for treatment of herpes and other viral infections using inhibitors of γ 1 34.5 expression or ICP34.5 activity.
Participants will receive rituximab 1000 mg intravenously on Days 1, 15, 168, and 182. Participants will also receive an initial dose of prednisone (0.5, 0.75, or 1.0 mg/kg orally once a day) with tapering beginning at Day 16 for 10 weeks to a dose of ≤ 10 mg/day. Participants will also receive acetaminophen 1000 mg orally and diphenhydramine 50 mg orally prior to study drug infusion.
Subject's habitual multi-purpose contact lens solution in Period 1, followed by 3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix contact lens solution in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
Anthracycline (ANT)-induced cardiotoxicity (AIC) is a particularly prominent form of cancer therapy-related cardiovascular toxicity leading to the limitations of ANTs in clinical practice. Even though AIC has drawn particular attention, the best way to treat it is remaining unclear. Updates to AIC therapy have been made possible by recent developments in research on the underlying processes of AIC. We review the current molecular pathways leading to AIC: 1) oxidative stress (OS) including enzymatic-induced and other mechanisms; 2) topoisomerase; 3) inflammatory response; 4) cardiac progenitor cell damage; 5) epigenetic changes; 6) renin-angiotensin-aldosterone system (RAAS) dysregulation. And we systematically discuss current prevention and treatment strategies and novel pathogenesis-based therapies for AIC: 1) dose reduction and change; 2) altering drug delivery methods; 3) antioxidants, dexrezosen, statina, RAAS inhibitors, and hypoglycemic drugs; 4) miRNA, natural phytochemicals, mesenchymal stem cells, and cardiac progenitor cells. We also offer a fresh perspective on the management of AIC by outlining the current dilemmas and challenges associated with its prevention and treatment.
The study is planned prospective and observational. The study started after approval of Erzincan Binali Yıldırım University Ethics Committee and taking written approval of patients. The study includes 84 patients who has surgery continues more then 1 hour, who is between ages 18-65, who is ASA I,II and III. The patients who has allergical reactions of the drugs used, neurological or neuromuscular diseases,the patients who use drugs effecting the neuromuscular junction, pregnant patients, electrolyte disregulations, major organ failures, liver failure, kidney failure, obese and cachectic patients are excluded from the study.

All patients will be informed and signed written approval 1 day before the surgery. Patients will be taken to the operating room, venous catheter will be applied on antecubital area. 3 channel EKG , SpO2 Monitor and noninvasive blood pressure monitorisation will be applied. The patients will be taken 2-4 litres of O2 with nasal cannula .The Train Of Four (TOF) Monitor will be placed on ulnar nerve on right wrist of the patients who has surgery under general anaesthesia. This is for stimulation of adductor pollicis muscle. Sedline (Masimo Electromyography(EMG) and Patient State Index(PSI)) Monitor will be placed on the frontal area of head. After the induction of general anaesthesia the investigators will wait for disappearance of eyelash reflex. TOF monitor will be calibrated and muscle relaxant will be applied. After TOF is %0 and disappearance of thumb movement the patient will be intubated. After surgery the investigators will apply muscle relaxant reversal drugs. PSI and EMG parameters will be recorded when TOF is %0, %25, %50,%75,%90. When TOF is %90 the investigators will extubate the patient. PSI and EMG parameters will be recorded after 5 minutes. The patient will be taken to the PACU room. On 5,10,30 minutes after surgery, the investigators will record aldrete score of patients.
In a new process for the prodn. of very finely divided carotenoids (carotenoid particle size essentially less than 1 micron), (A) a carotenoid is dissolved in a gas in the supercritical state (i.e. at a temp. above the critical temp. and under a pressure greater than the critical pressure); (B) the resulting soln. is dispersed in a suitable aq. colloidal matrix; (C) the dispersion is depressurised, and (D) the prod. is opt. converted in a conventional manner into a water-dispersible carotenoid-contg. powder mixt. The carotenoids are for use in colouring foodstuffs, pharmaceuticals or cosmetics, or for administration to poultry to give improved egg-yolk pigmentation.
Alzheimer's disease (AD), the most common cause of dementia, leads to neurodegeneration and cognitive decline. We investigated the therapeutic effects of L-carnitine on cognitive performance and anxiety-like behavior in a rat model of AD induced by unilateral intracerebroventricular injection of β-amyloid1-42 (Aβ1-42). L-carnitine (100 mg/kg/day) was administered intraperitoneally for 28 consecutive days. Following this, the open-field test, novel object recognition test, elevated plus-maze test, Barnes maze test, and passive avoidance learning test were used to assess locomotor activity, recognition memory, anxiety-like behavior, spatial memory, and passive avoidance memory, respectively. Plasma and hippocampal oxidative stress markers, including total oxidant status (TOS) and total antioxidant capacity (TAC), were examined. In addition, histological investigations were performed in the dentate gyrus of the hippocampus using Congo red staining and hematoxylin and eosin staining. The injection of Aβ1-42 resulted in cognitive deficits and increased anxiety-like behavior. These changes were associated with an imbalance of oxidants and antioxidants in plasma and the hippocampus. Also, neuronal death and Aβ plaque accumulation were increased in the hippocampal dentate gyrus region. However, injection of L-carnitine improved recognition memory, spatial memory, and passive avoidance memory in AD rats. These findings provide evidence that L-carnitine may alleviate anxiety-like behavior and cognitive deficits induced by Aβ1-42 through modulating oxidative-antioxidant status and preventing Aβ plaque accumulation and neuronal death.
Patients receive CI-994 orally daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for 30 days and then every 2 months.
The invention discloses an application of a Pingxuan capsule in preparing medicine capable of treating vasculitis. The formula of the Pingxuan capsule comprises Chinese aralis, woody hawkbeard root, gastrodia elata, pseudo-ginseng, rhizoma polygonati, hairyvein agrimony and cleavers. The Pingxuan capsule is a capsule, and each capsule has a weight of 0.5g. The Pingxuan capsule is orally taken three times a day, and two capsules are taken each time. The Pingxuan capsule has the functions of nourishing liver and kidney, calming the liver and suppressing the hyperactive yang, is used for treating giddiness, dizziness, palpitation, tinnitus, insomnia, dreamful sleep and weakness at waist and knee caused by deficiency of liver and kidney and liver-yang flaring up. At present, researchers find that the Pingxuan capsule can be used for treating the vasculitis.
Aim: to attest the abiding efficacy and safety of acupuncture for migraine prophylaxis Design: A open-label randomized controlled trial will be performed in Chengdu, Hunan and Chongqing province. Two hundred and forty-three participants will be randomly assign to acupoint-meridian group, non-acupoint-meridian group, and wait-and-see group. Each participants will receive 20 sessions of acupuncture in 4 weeks, with a duration of 30 minutes in a session. After all the treatments was accomplished, there will be 5 times follow-ups in the impending every 4 weeks. The primary outcome is frequency of migraine attacks 16 weeks after inclusion. Secondary outcomes include frequency of migraine attacks at the 4th and 24th week, headache severity, MSQ(Migraine Specific Quality of Life Questionnaire MSQ Version2.1), etc.
2-cyanoacrylate esters of general formula (I) R = straight- or branched aliphatic hydrocarbons (C2-8, pref. C2-6) Rf = straight- or branched fluoroaliphatic groups (C1-8, pref. C1-5) pref. at least one F-atom per C-atom and ending in CF3 X = R-H, CH3, Rf or H; pref. Rf or H (I) polymerise quickly to adhesives with great strength in the presence of water and with small change in volume upon polymerisation. They may be used esp. in applications in dentistry such as in orthodontic-, prosthodontic- and endodontic applications. (I) May also be polymerised to form addition- and copolymers. Compns. contng. (I) give very strong bonds of exceptional stability against decomposition by moisture in the mouth. They have no unfavourable effect on tooth enamel and minimal toxicity on dentine. (I) Hardens at body temp. in less than 2 mins. which gives enough time for manipulation. The low viscosity gives some flow in very small crevices and strong bonding to the tooth surface.
INTRODUCTION: Currently, kidney disease is an increasing major health problem worldwide. It is expected to be the 5th ranked cause of death by 2040. If it is early detected, further complication caused by kidney disease will be minimized. An assessment of impaired glomerular filtration rate (eGFR) has potential aids in early identification and treatment of kidney disease. However, in hospital practice instead of using eGFR, direct measurement of serum creatinine level is used for assessing renal function. Hence, this study is aimed to assess the magnitude and associated factors of impaired glomerular filtration rate among admitted patients in Wolkite University Specialized Teaching Hospital (WKUSTH).
OBJECTIVE: To assess the magnitude and associated factors of impaired glomerular filtration rate in WKUSTH, Ethiopia 2023.
METHOD: Institutional based cross-sectional study with secondary data was conducted. 338 participants were selected by a convenient sampling technique. Epidata 3.1 version for data entry and SPSS version 20 for data analysis was used. Bivariate analysis was used to screen candidate variables for multivariate analysis. In the multivariate analysis a P-value < 0.05 were considered statistically significant.
RESULTS: The study enrolled 338 patients admitted to WUSTH. Seventy (20.7%) (95% CI: 16.6-25.4%) of them had impaired eGFR according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and Modification of Diet in Renal Disease (MDRD-4). older age (AOR 3.38, 95% CI; 1.31, 8.71), hypertension (AOR 17.8, 95% CI; 7.75, 41.22), anemia (AOR 2.51, 95% CI; 1.11, 5.83) DM (AOR 11.2, 95% CI; 4.11, 30.73), and high BMI (AOR 7.56, 95% CI; 3.16, 18.08), were independently associated with impaired eGFR.
CONCLUSIONS: The magnitude of impaired eGFR was prevalent among adult patients admitted to WKUSTH medical ward with different medical conditions. Old age, Hypertension, Diabetes, high body mass index, and Anemia were significantly associated with impaired eGFR both in CKD-EPI and MDRD-4 equation. Estimation of GFR for all hospitalized adults with known CKD risk factors might help in early detection of CKD and prevent complications.
The invention provides a manufacturing technology of a 3D printed mask. The technology includes the following steps that under sterile vacuum conditions, according to human facial profiles, collagen gel and mask essence are sequentially stacked and printed through a 3D printer to obtain the 3D printed mask. The mask is manufactured through the 3D printing technology, the mask can be obtained by sequentially stacking and printing the collagen gel and the mask essence, the method is simple, and consumed time is short. Besides, the high-temperature process is not needed during printing, and effective components of the mask essence can be completely stored. Besides, a porous mask support is formed through the collagen gel in the vacuum condition, and the mask essence can be adsorbed to the largest extent. The obtained 3D printed mask is specialized according to individuation of the human facial profiles, and can completely fit with pores on human face skin.
<P>PROBLEM TO BE SOLVED: To efficiently add photograph order information in medical image photography by using a personal digital assistant.  <P>SOLUTION: In this medical image photography system 100, when addition of photograph order information is instructed from an input part 42, a PDA 4 reads a bar-code on an ID card of a doctor via a reading part 44 for authentication, and then, displays an additional image for the photograph order information in a display part 43. When the photograph order information to be added is inputted, the PDA 4 adds and updates the photograph order information to transmit it to a control device 1. The control device 1 adds the received photograph order information to a photograph order information file 171 for updating it, and at the same time, transfers the received photograph order information to an information management device 2. The information management device 2 adds the received photograph order information to update the photograph order information DB.  <P>COPYRIGHT: (C)2004,JPO
The recommended usual starting dose is 10 mg once a day in the evening. The recommended dosing range is 10 to 40 mg/day; the maximum recommended dose is 40 mg/day. Doses should be individualized according to the recommended goal of therapy [see NCEP Pediatric Panel Guidelines and Clinical Studies ( 14.2 )]. Adjustments should be made at intervals of 4 weeks or more. 

—————————————————————————————————————————————————————

1 National Cholesterol Education Program (NCEP): Highlights of the Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics. 89(3):495-501. 1992.
PURPOSE: A SiO2 shell/MB-Au nanocore complex is provided to apply as a biosensor and molecular image contrast agent by having an excellent surface enhanced raman scattering (SERS) effect with hybridizing methylene blue with Au nano material. CONSTITUTION: A SiO2 shell/MB-Au nanocore complex comprises a coating layer and a core. The coating layer contains silica, and the core contains a gold (Au) nano material in which methylene blue is hybridized. The gold nano material is multicore gold nanoparticle or a gold nanorod. An average thickness of the coating layer is 1-500 nm. The SiO2 shell/MB-Au nanocore complex is used for a biosensor, a molecular image contrast agent, a capsule type endoscope and a treatment of cancer. The SiO2 shell/MB-Au nanocore complex enable a diagnosis of cancer and treatment of cancer at the same time. A manufacturing method of the SiO2 shell/MB-Au nanocore complex comprises the following step. The methylene blue and the gold nano material are hybridized by using the silica coating method.
OBJECTIVES: I. Determine the maximum dose that can be administered in an ambulatory setting among three dose regimens in children with stage IV neuroblastoma. II. Determine the highest tolerated level if a sustained increase in NK-cell number is observed. III. Determine the type, duration, and reversibility of side effects at the three dose levels. IV. Confirm the chosen dose level.

OUTLINE: This is a randomized, parallel, open label, multicenter study. Part I: Patients receive one of three doses of interleukin-2 (IL-2) subcutaneously beginning 20 to 40 days following autologous stem cell reinfusion. IL-2 is administered for 5 consecutive days every 14 days for up to 3 months, for a total of 6 courses. Cohorts of 5 patients are entered at each dose level of IL-2 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 3 or more patients experience dose limiting toxicity. Part II: Additional patients receive IL-2 at the dose level below the MTD. These patients are stratified according to prior therapy (melphalan plus megatherapy vs total body irradiation or meta-iodobenzylguanidine scan plus melphalan vs busulfan containing regimens). Patients are followed at 1 week.

PROJECTED ACCRUAL: Approximately 25 patients will be accrued for this study.
PURPOSE: To obtain a copper-chondroitin sulfate complex exhibiting excellent pharmacological characteristics, esp. antiinflammatory activity, inflammation subsiding activity, antioxidant activity and antiradical activity. CONSTITUTION: First, chondroitin sulfate or sodium chondroitin sulfate is reacted with a cupric salt such as CuCl2 .2H2 O or CuSO4 .5H<2> O in an aqueous solution to form a complex containing 0.5-10wt.% Cu. Subsequently, an organic solvent (pref. 1-4C alcohol) is added to the system to precipitate the complex, thus obtaining a copper-chondroitin sulfate complex, which is capable of inhibiting at concentrations of micromole order elastase, cathepsin, galactosidase and glucuronidase, thus being used for treating inflammatory diseases due to various sources (e.g. degenerative arthropathy, chronic arthrorheumatism, hip joint arthrosis, spondylarthrosis).
Patients receive bleomycin IV over 10 minutes on days 1, 8, and 15, etoposide IV over 1-2 hours on days 1-5, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and/or chest x-ray as well as blood sample collection throughout the trial. Patients may also undergo a tumor biopsy throughout the trial. Patients undergo a pulmonary function test on study.
OBJECTIVES: As a heterogeneous disease, asthma is characterized by airway hyperresponsiveness, airway inflammation, and airway mucus hypersecretion. According to the pathological changes, symptoms, preventive and treatment methods, asthma can be divided into TH2-high and TH2-low asthma. We show that the expression of the tumor biomarker human epididymis protein 4 (HE4) was significantly increased in TH2-high asthma group, while there was no marked difference in its expression between TH2-low asthma and healthy control groups. HE4 levels were significantly increased in plasma, induced sputum, and alveolar lavage fluid (BALF) samples and airway epithelial cells from TH2-high asthma group, showing that HE4 has a possible role in the pathogenesis of TH2-high asthma.
METHODS: Using RT-qPCR, ELISA, Western blot (WB), and immunohistochemistry, we assessed differences in HE4 expression in plasma, induced sputum, BALF, and airway epithelial cells among patients with the TH2-related asthma subtypes and healthy controls. To explore the role of HE4 in TH2-high asthma, we conducted a correlation analysis between HE4 levels in plasma, induced sputum, BALF, and airway epithelial cells and multiple indicators of airway eosinophilic inflammation, airway mucus secretion, and airway remodeling.
CONCLUSION: We found for the first time that HE4 was differentially expressed in the TH2-related asthma subtypes. In TH2-high asthma, HE4 levels were markedly elevated in airway epithelial cells, plasma, induced sputum, and BALF. HE4 may play an important role in various pathogenic mechanisms of asthma, such as airway eosinophilic inflammation, airway mucus secretion, and airway remodeling. HE4 in plasma may be a clinically biomarker for differentiating TH2-related asthma subtypes.
BACKGROUND: Lifestyle changes, such as those related to the COVID-19 pandemic, including alterations in physical activity and dietary habits, are known to affect pregnancy outcomes. In particular, suboptimal intrauterine conditions during pregnancy are known to influence not only fetal growth but also growth during infancy. However, research on the impact of the environmental changes caused by the COVID-19 pandemic on the growth of infants and children during their early years is lacking. To address this issue, this study evaluated the effect of the COVID-19 pandemic on obesity in infants.
METHODS: This retrospective cohort study used the data collected from the Korea National Health Insurance (KNHI) claims database. The data of 1985,678 women who delivered infants between 2015 and 2021 were collected. Women who delivered during the pandemic and those who delivered during the pre-pandemic period were matched in a 1:1 frequency-matched pair procedure for factors such as age, hypertension, diabetes mellitus, preeclampsia, gestational diabetes mellitus, mode of delivery, gestational age at delivery, offspring sex, and birth weight. Finally, 197,580 women were enrolled. The weight and head circumference of infants (4-6 months of age) of the COVID-19 pandemic group were compared with those of the pre-pandemic group.
RESULTS: The COVID-19 pandemic group infants exhibited significantly higher weight and prevalence of obesity at 4-6 months of age compared to infants in the pre-pandemic group. After adjustment for covariates, pandemic group infants had a higher risk of obesity (odds ratio: 1.54, 95% confidence interval: 1.51-1.57) compared to the pre-pandemic group infants.
CONCLUSION: The COVID-19 pandemic has had a notable impact on the weight of infants aged 4-6 months. This suggests that pandemic conditions may influence the growth of newborns, underscoring the importance of monitoring and assessing trends in the growth of infants born during such crises.